残肝体积不足的肝恶性肿瘤患者转化治疗的研究进展

Research progress on conversion therapy for patients with malignant liver tumors with inadequate remnant liver volume

对于肝脏原发或局限性转移的恶性肿瘤患者,获得长期生存的唯一机会是完全切除肝脏肿瘤。但肝切除术后肝衰竭(PHLF)仍然是肝切除术后主要死亡原因,而残余肝体积不足已经被证明是PHLF的主要危险因素。目前已有多种方法来进行术前转化治疗,门静脉栓塞和联合肝脏离断和门静脉结扎的二步肝切除术是目前应用最多的两种方法,但各自都有明显的优缺点。随着恶性肿瘤综合治疗的发展,多种治疗方法正在探索中,本研究对比了不同的转化治疗方法,旨在为临床提供参考。

For patients with primary or locally metastatic malignant liver tumors,the only chance for long-term survival is complete resection of the liver tumors.However,post-hepatectomy liver failure(PHLF)remains a major cause of mortality after liver resection,and inadequate future liver remnant has been proven to be a major risk factor for PHLF.Currently,various methods exist for preoperative conversion therapy.Portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy are the two most widely used methods.However,each method has its distinct advantages and disadvantages.With the development of comprehensive treatment for malignant tumors,several treatment methods are under exploration.This study compares different conversion therapy methods,aiming to provide clinical references.